RAD17P1: A Potential Drug Target Or Biomarker for Cancer (G9207)

Target Name: RAD17P1

NCBI ID: G9207

RAD17P1

Other Name(s): RAD17 pseudogene 1 | RAD17 homolog (S. pombe) pseudogene 1 | HRAD17P1

RAD17P1: A Potential Drug Target Or Biomarker for Cancer

RAD17P1, also known as RAD17 gene, is a gene located on chromosome 17 that has been identified as a potential drug target or biomarker for various diseases, including cancer. The RAD17 gene has been shown to be involved in various cellular processes that are crucial for cell growth, development, and survival. In this article, we will discuss the research on RAD17P1 and its potential as a drug target or biomarker.

History of the RAD17 gene

The RAD17 gene was first identified in the 1980s by researchers who were studying the genetics of cancer. They found that people with certain genetic mutations, such as those in the RAD17 gene, were at a higher risk of developing certain types of cancer. Since then, numerous studies have confirmed the involvement of the RAD17 gene in various cellular processes that are important for cancer development and progression.

Expression of the RAD17 gene

The RAD17 gene is expressed in various tissues and cells of the body, including the liver, lung, and brain. It is primarily expressed in the liver, with lower levels of expression found in the lung and brain. The RAD17 gene is a member of the P16 gene family, which is known for its involvement in cell cycle regulation and apoptosis.

In cancer, the RAD17 gene is often overexpressed, which means that the number of RAD17 genes expressed in a cell is higher than normal. This increase in RAD17 gene expression can lead to the formation of RAD17-containing protein aggregates, which are thought to play a role in the development and progression of cancer.

Drug targeting using RAD17P1

Drug targeting using RAD17P1 involves the use of small molecules or antibodies to specifically target the RAD17 gene and reduce its expression. This approach is based on the fact that drugs can either inhibit the activity of the RAD17 gene or stimulate its expression.

One of the most promising strategies for drug targeting using RAD17P1 is the use of small molecules that inhibit the activity of the RAD17 gene. These drugs work by binding to specific regions of the RAD17 gene and preventing it from being translated into protein. One such drug is called RAD17 inhibitor, which is a small molecule that binds to the RAD17 gene and inhibits its activity.

Another approach to drug targeting using RAD17P1 is the use of antibodies that recognize and target specific regions of the RAD17 gene. These antibodies can be used to either block the activity of the RAD17 gene or stimulate its expression. One such antibody is called RAD17 antibody, which recognizes a specific region of the RAD17 gene and can be used to inhibit or stimulate its activity.

Biomarker potential of RAD17P1

RAD17P1 has been shown to be involved in various cellular processes that are important for cancer development and progression. As a result, it has great potential as a biomarker for cancer. By measuring the expression of RAD17P1, researchers can monitor the effectiveness of different treatments and determine whether a patient is responding to treatment.

One of the most promising applications of RAD17P1 as a biomarker is its potential to be used as a companion diagnostic (CD) for cancer. By measuring the expression of RAD17P1 in cancer cells, researchers can determine whether a patient has a particular type of cancer that is sensitive to a particular treatment. This approach has the potential to improve treatment outcomes by identifying patients who are most likely to respond to a particular treatment.

Another potential application of RAD17P1 as a biomarker is its use in liquid biopsy. Liquid biopsy is a technique that involves the collection of small samples of cancer cells from the body and then testing them for various genetic changes, including those in the RAD17 gene. This approach has the potential to

Protein Name: RAD17 Pseudogene 1

The "RAD17P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD17P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets